



DT06 Rec'd PCT/PTO

13 AUG 2002

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Liang et al.

Serial No. 10/070,560

Filed: March 8, 2002

For: Method of Producing and Purifying
Endostatin Protein)
)
)
) Art Unit: Not Yet Assigned
)
) Examiner: Not Yet Assigned
)
)
)
)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.


This Supplemental Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be required. However, if a first Office Action on the merits has issued, please consider this Information Disclosure Statement under 37 C.F.R. 1.97(c). The Commissioner is hereby authorized to charge the applicable fees, if any, to Deposit Account No. 11-0855.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 08, 2002


Jamie L. Greene - Reg. No. 32,467


The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,



Jamie L. Greene
Reg. No. 32,467

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 05213-0551US (43170-258385)



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

Sheet 1 of 7

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ⁴	Kind Code ³ (if known)			
	1	60/80728		MIXSON, James A.	06/27/2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Complete if Known

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

7

Application No.

10/070,560

Filing Date

03/08/2002

First Named Inventor

Liang et al.

Group Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

05213-0551US (43170-258385)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	2	Author: _____ Title: Chapter 12: Vectors for Gene Therapy Publ: _____ Current Protocols in Human Genetics Vol/Iss: _____ Pages: _____ Date: 1997	
	3	Author: BOUSSIF, O. et al. Title: A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i> : Polyethylenimine Publ: _____ Proc. Natl. Acad. Sci. USA Vol/Iss: 92 Pages: 7297-7301 Date: 08/1995	
	4	Author: CALOS, MICHELE P. Title: The potential of extrachromosomal replicating vectors for gene therapy Publ: _____ TIG Vol/Iss: 12 (11) Pages: 463-466 Date: 11/1996	
	5	Author: CHEN, P. et al. Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene Publ: _____ Science Vol/Iss: 250 Pages: 1576-1579 Date: 12/1990	
	6	Author: CHENG, PI-WAN Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin Publ: _____ Human Gene Therapy Vol/Iss: 7 Pages: 275-282 Date: 02/10/199	
	7	Author: CLAPP, C. et al. Title: The 16-kilodalton N-terminal Fragment Of Human Prolactin Is A Potent Inhibitor Of Angiogenesis Publ: _____ Endocrinology Vol/Iss: 133 Pages: 1292-1299 Date: 03/01/93	
	8	Author: DAMERON, K.M. et al. Title: Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1 Publ: _____ Science Vol/Iss: 265 Pages: 1582-1584 Date: 09/09/94	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	10/070,560
				Filing Date	03/08/2002
				First Named Inventor	Liang et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	7	Attorney Docket Number	05213-0551US (43170-258385)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
	9	Author: DARDIK, R. et al Title: The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains Publ: _____ <u>Eur J Biochem</u> Vol/Iss: 168 (2) Pages: 347-355 Date: 10/15/198			
	10	Author: DEBS, R.J, et al. Title: Regulation of Gene Expression <i>in Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor Publ: _____ <u>The Journal of Biological Chemistry</u> Vol/Iss: 265 (18) Pages: 10189-10192 Date: 06/25/199			
	11	Author: DIXIT, V.M. et al. Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation Publ: _____ <u>Proc. Natl. Acad. Sci. USA</u> Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985			
	12	Author: FAN et al. Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Publ: _____ <u>Trends in Pharmacological Sciences</u> Vol/Iss: 16 (2) Pages: 57-66 Date: 02/95			
	13	Author: FIDLER et al. Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis Publ: _____ <u>Cell</u> Vol/Iss: 79(2) Pages: 185-188 Date: 10/21/94			
	14	Author: FUJIWARA, T. et al. Title: Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type <i>p53</i> Gene Publ: _____ <u>Cancer Research</u> Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199			
	15	Author: GOLDMAN, C.K. et al. Title: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer Publ: _____ <u>Nature Biotechnology</u> Vol/Iss: 15 Pages: 462-466 Date: 05/1997			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

Sheet 4 of 7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	16	Author: HAWKINS, MICHAEL J, Title: Clinical trials of antiangiogenic agents Publ: M.D. <u>Current Opinion in Oncology</u> Vol/Iss: 7 Pages: 90-93 Date: 1995	
	17	Author: KING, RALPH D. Jr. Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block Publ: <u>Wall Street Journal</u> Vol/Iss: Pages: A1, A8 Date: 11/12/199	
	18	Author: KOSFELD, M.D. et al. Title: Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin Publ: <u>The Journal of Biological Chemistry</u> Vol/Iss: 268 (12) Pages: 8808-8814 Date: 1993	
	19	Author: LESOON-WOOD, L.A. et al. Title: Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice Publ: <u>Human Gene Therapy</u> Vol/Iss: 6 Pages: 395-405 Date: 04/1995	
	20	Author: MAIONE, T.E. et al. Title: Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity Publ: <u>Cancer Research</u> Vol/Iss: 51 Pages: 2077-2083 Date: 04/15/199	
	21	Author: MARSHALL, ELIOT Title: Gene Therapy's Growing Pains Publ: <u>Science</u> Vol/Iss: 269 Pages: 1050-1055 Date: 08/25/199	
	22	Author: MILLAUER, B. et al. Title: Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant Publ: <u>Nature</u> Vol/Iss: 367 Pages: 576-579 Date: 02/10/94	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	10/070,560
				Filing Date	03/08/2002
				First Named Inventor	Liang et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	7	Attorney Docket Number	05213-0551US (43170-258385)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	23	Author: O'REILLY et al. Title: Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma Publi: _____ Cell _____ Vol/Iss: 79 Pages: 315-328 Date: 10/21/94			
	24	Author: O'REILLY et al. Title: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Publi: _____ Cell _____ Vol/Iss: 88 Pages: 277-285 Date: 01/24/97			
	25	Author: PARK et al. Title: Development of liposome- and anti-HER2 immunoliposomeplasmid complexes for efficient and selective gene therapy Publi: _____ Proceedings of the American Association for Cancer Research Vol/Iss: 38 Pages: 342 Date: 03/1997			
	26	Author: PASQUALINI, R. et al. Title: αv Integrins as receptors for tumor targeting by circulating ligands Publi: _____ Nature Biotechnology Vol/Iss: 15 Pages: 542-546 Date: 06/1997			
	27	Author: PASQUALINI, R. et al. Title: Organ targeting <i>in vivo</i> using phage display peptide libraries Publi: _____ Nature Vol/Iss: 380 Pages: 364-166 Date: 03/28/199			
	28	Author: SAIKI et al. Title: Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD) Publi: _____ Jpn. J. Cancer Research Vol/Iss: 81 Pages: 668-675 Date: 1990			
	29	Author: SAKAMOTO, N. et al. Title: Inhibition of Angiogenesis And Tumor Growth By A Synthetic Laminin Peptide. Cdpgyigr-nh2 Publi: _____ Cancer Research Vol/Iss: 51 Pages: 903-906 Date: 02/01/91			

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Complete if Known

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

7

Application No.

10/070,560

Filing Date

03/08/2002

First Named Inventor

Liang et al.

Group Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

05213-0551US (43170-258385)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁴
	30	<p>Author: SHEIKH et al. Title: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines</p> <p>Publ: <u>Oncogene</u> Vol/Iss: 11 Pages: 1899-1905 Date: 1995</p>	
	31	<p>Author: TANAKA, T. et al. Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth</p> <p>Publ: <u>Nature Medicine</u> Vol/Iss: 3 Pages: 437-442 Date: 04/1997</p>	
	32	<p>Author: TOLSMA, S.S. et al. Title: Peptides Derived From Two Separate Domains Of The Matrix Protein Thrombospondin-1 Have Antiangiogenic Activity</p> <p>Publ: <u>Journal of Cell Biology</u> Vol/Iss: 122 Pages: 497-511 Date: 07/1993</p>	
	33	<p>Author: WEINSTAT-SASLOW, D.L. et al. Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and</p> <p>Publ: <u>Cancer Research</u> Vol/Iss: 54 Pages: 6504-6511 Date: 1994</p>	
	34	<p>Author: XU, M. et al. Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes</p> <p>Publ: <u>Molecular Genetics and Metabolism</u> Vol/Iss: 64 Pages: 001-005 Date: 1998</p>	
	35	<p>Author: XU, M. et al. Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breast Cancer <i>In Vivo</i></p> <p>Publ: <u>Molecular Genetics and Metabolism</u> Vol/Iss: 63 Pages: 103-109 Date: 1998</p>	
	36	<p>Author: XU, M. et al. Title: Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity</p> <p>Publ: <u>Human Gene Therapy</u> Vol/Iss: 8 Pages: 177-185 Date: 01/20/199</p>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	10/070,560
				Filing Date	03/08/2002
				First Named Inventor	Liang et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	7	of	7	Attorney Docket Number	05213-0551US (43170-258385)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	37	Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA, LUNG AND BREAST CARCINOMA CELL Publ: <u>Int. J. Cancer</u> Vol/Iss: 59 Pages: 191-195 Date: 1994			
	38	Author: ZHU, N. et al. Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Publ: <u>Science</u> Vol/Iss: 261 Pages: 209-211 Date: 07/09/199			

Examiner Signature	/Shulamith Shafer/	Date Considered	08/27/2008
-----------------------	--------------------	--------------------	------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.